Form 4 for APRE Aprea Therapeutics, Inc.

Accepted 2022-03-14 00:00:00 ET · period of report 2022-03-10 · accession 0001104659-22-033392 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2022-03-14	2022-03-10	APRE	Korbel Gregory Alan	SVP, Chief Business Off, Dir	F - Tax	$1.82	-1,989	29.9K	-6%	-$3,620
D	2022-03-14	2022-03-10	APRE	Korbel Gregory Alan	SVP, Chief Business Off, Dir	A - Grant	$0.00	+16.0K	31.8K	+101%	$0
D	2022-03-14	2022-03-10	APRE	Korbel Gregory Alan	SVP, Chief Business Off, Dir	A - Grant	$0.00	+72.6K	72.6K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2022-03-10	F	D	1,989	$1.82	29,852	D	—	—	(F2) Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 5,000 restricted stock units
2	Common	Common Stock	2022-03-10	A	A	16,000	$0.00	31,841	D	—	—	(F1) These shares represent restricted stock units which were granted on March 10, 2022, and which will vest and be settled in common stock as follows: (i) 5,333 shares on March 10, 2023, (ii) 5,333 shares on March 10, 2024 and (iii) 5,334 shares on March 10, 2025, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
3	Derivative	Stock Option (right to Buy)	2022-03-10	A	A	72,600	$0.00	72,600	D	$1.82 · — to 2032-03-10	72,600 Common Stock	(F3) Twenty-five percent of these options vest on March 10, 2023, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.